Facebook
Twitter
Telegram
Report an ErrorHalozyme Therapeutics Financial Ratios 2011-2024 | HALO
Annual Financial Ratios Halozyme Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
16.9 | 33.8 | 12.4 | 47.7 | -38.8 | -28.6 | 41.6 | -13.9 | -34.6 | -25.6 | -21.6 | -14.7 | -55.1 |
P/S |
5.7 | 10.4 | 11.3 | 23.0 | 14.3 | 15.1 | 8.3 | 9.8 | 8.3 | 23.3 | 32.9 | 18.6 | 19.4 |
EPS |
2.1 | 1.5 | 2.9 | 0.9 | -0.5 | -0.6 | 0.5 | -0.8 | -0.2 | -0.6 | -0.7 | -0.5 | -0.2 |
EV (Enterprise Value) |
6.28 B | 8.28 B | 4.87 B | 6.02 B | 3.16 B | 2.43 B | 2.76 B | 1.66 B | 1.21 B | 1.82 B | 1.89 B | 774 M | 1.09 B |
EBITDA per Share |
2.64 | 2 | 1.98 | 1.08 | -0.44 | -0.466 | 0.61 | -0.631 | -0.203 | -0.499 | -0.702 | -0.473 | -0.183 |
EV/EBITDA |
17.2 | 48.0 | -48.6 | -35.3 | 31.9 | -19.6 | -43.5 | -28.4 | -23.0 | -13.7 | -55.4 | ||
PEG |
-0.36 | -0.38 | -0.1 | -0.46 | 3.62 | 0.13 | -0.27 | -0.06 | 0.62 | 1.05 | -0.4 | -0.1 | 0.83 |
P/B |
56.7 | 40.3 | 4.5 | 10.6 | 30.6 | 9.2 | 12.6 | -44.2 | 25.9 | 42.4 | -90.1 | 16.1 | 100.0 |
P/CF |
12.2 | 28.5 | 16.7 | 111.1 | -31.3 | -42.4 | 19.8 | -26.9 | -28.3 | -35.8 | -34.9 | -12.0 | -31.0 |
ROE % |
336.00 | 119.04 | 204.47 | 85.46 | -78.72 | -32.28 | 30.22 | 317.18 | -74.96 | -165.35 | 417.59 | -109.62 | -181.37 |
ROA % |
16.25 | 10.98 | 36.46 | 22.26 | -12.77 | -18.25 | 12.11 | -39.39 | -17.73 | -41.20 | -82.01 | -39.75 | -30.06 |
ROCE % |
402.79 | 157.56 | 140.09 | 95.50 | -14.08 | -23.83 | 20.84 | -40.21 | -23.00 | -44.50 | -105.36 | -46.32 | -40.94 |
Current Ratio |
1.1 | 1.1 | - | - | 6.3 | 2.9 | 3.9 | 4.7 | 2.8 | 6.6 | 3.7 | 6.9 | 3.7 |
DSO |
- | - | 40.2 | 107.2 | 110.7 | 72.1 | 25.5 | 39.0 | 87.6 | 44.3 | 60.6 | 135.4 | 14.7 |
DIO |
216.1 | 201.8 | 257.0 | 379.2 | 235.3 | 814.7 | 60.3 | 160.7 | 118.4 | 102.9 | 360.6 | 890.7 | 803.0 |
DPO |
28.0 | 25.2 | 7.8 | 35.2 | 51.6 | 146.9 | 93.1 | 39.3 | 56.2 | 48.2 | 183.2 | 757.6 | 10697.8 |
Operating Cycle |
216.1 | 201.8 | 297.2 | 486.4 | 346.0 | 886.8 | 85.8 | 199.8 | 206.0 | 147.2 | 421.2 | 1026.1 | 817.8 |
Cash Conversion Cycle |
188.1 | 176.6 | 289.5 | 451.2 | 294.4 | 740.0 | -7.3 | 160.4 | 149.9 | 99.0 | 238.0 | 268.5 | -9880.0 |
All numbers in USD currency
Quarterly Financial Ratios Halozyme Therapeutics
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.61 | - | 0.62 | 0.57 | 0.29 | - | 0.45 | 0.16 | 0.44 | - | 1.53 | 0.64 | 0.2 | 0.54 | 0.27 | 0.19 | -0.04 | -0.24 | -0.17 | -0.1 | 0.01 | -0.01 | -0.19 | -0.16 | -0.19 | 870 | 20 | -230 | -260 | 0.03 | -0.23 | -0.21 | -0.16 | 0.03 | -0.19 | 0.02 | -0.12 | -0.04 | -0.16 | -0.13 | -0.22 | -0.19 | -0.17 | -0.2 | -0.17 | -0.04 | -0.18 | -0.13 | -0.14 | -0.18 | 0.05 | 0.03 | -0.1 |
EBITDA per Share |
0.77 | - | 0.69 | 0.74 | 0.42 | - | 0.62 | 0.25 | 0.56 | - | 0.54 | 0.66 | 0.37 | - | 0.3 | 0.22 | -0.02 | - | -0.16 | -0.09 | 0.03 | - | -0.17 | -0.14 | -0.16 | - | 0.06 | -0.19 | -0.21 | - | -0.17 | -0.17 | -0.12 | - | -0.17 | 0.04 | -0.11 | - | -0.14 | -0.11 | -0.21 | - | -0.16 | -0.19 | -0.16 | - | -0.17 | -0.12 | -0.14 | - | 0.06 | 0.04 | -0.09 |
ROE % |
158.39 | 142.50 | 206.04 | 236.75 | 194.99 | 94.38 | 171.27 | 184.62 | 253.26 | 194.54 | 242.97 | 190.05 | 130.77 | 85.46 | -0.46 | -51.69 | -84.72 | -78.72 | -42.09 | -26.02 | -19.28 | -32.28 | 28.03 | 40.54 | 34.98 | 30.22 | 55.08 | 142.88 | 240.38 | 317.18 | 169.18 | 12.74 | -132.50 | -239.59 | -188.66 | -170.38 | -147.23 | -165.35 | -42.61 | 102.94 | 256.91 | 417.60 | 298.60 | 161.14 | 17.82 | -109.62 | -269.53 | -181.20 | -123.91 | -181.36 | 47.39 | 28.59 | -88.40 |
ROA % |
16.95 | 10.78 | 14.09 | 13.07 | 10.22 | 9.75 | 28.02 | 42.99 | 50.63 | 30.07 | 42.69 | 30.66 | 26.20 | 22.26 | 3.56 | -7.10 | -14.14 | -12.77 | -7.17 | -9.08 | -11.69 | -18.25 | 6.06 | 12.92 | 12.20 | 12.11 | -22.19 | -33.78 | -38.14 | -39.39 | -43.99 | -48.84 | -53.35 | -56.67 | -44.78 | -41.08 | -36.10 | -41.20 | -59.62 | -66.35 | -79.05 | -82.01 | -63.68 | -59.58 | -47.48 | -39.75 | -64.48 | -41.78 | -26.63 | -30.06 | 7.85 | 4.74 | -14.65 |
ROCE % |
187.13 | 179.67 | 265.55 | 316.00 | 265.07 | 126.57 | 153.40 | 94.36 | 160.45 | 179.59 | 206.27 | 206.12 | 147.98 | 44.11 | 17.37 | -36.04 | -70.84 | -38.74 | -48.97 | -32.47 | -25.30 | -27.83 | -23.95 | -9.84 | -14.00 | -21.56 | 48.46 | 114.60 | 193.71 | 186.68 | 132.64 | 8.58 | -48.46 | -76.55 | -122.56 | -114.53 | -160.50 | -143.12 | -50.61 | 87.92 | 234.71 | 295.70 | 254.70 | 121.18 | -18.23 | -100.75 | -53.47 | 34.80 | 91.96 | -12.94 | 47.27 | 28.40 | -88.62 |
Current Ratio |
1.1 | 1.1 | 1.1 | 1.1 | 1.0 | 1.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
97.5 | - | 92.0 | 86.0 | 107.5 | - | 92.3 | 90.8 | 79.7 | - | 104.5 | 80.8 | 95.4 | 73.3 | 136.5 | 161.5 | 282.8 | 101.1 | 117.3 | 138.6 | 71.7 | 45.5 | 107.1 | 77.8 | 77.0 | 10.7 | 31.7 | 59.8 | 58.4 | 36.7 | 44.9 | 42.9 | 51.6 | 75.8 | 142.3 | 68.2 | 101.6 | 27.5 | 57.2 | 45.4 | 69.6 | 66.4 | 51.8 | 57.4 | 95.6 | 65.8 | 268.6 | 184.7 | 110.2 | 85.6 | 9.0 | 8.9 | - |
DIO |
476.9 | - | 217.5 | 218.6 | 269.4 | - | 193.7 | 195.4 | 291.3 | - | 281.1 | 231.7 | 298.2 | - | 995.5 | 965.7 | 710.4 | - | 120.0 | 1427.3 | 510.2 | - | 3298.0 | 2469.5 | 415.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
40.5 | - | 24.5 | 17.1 | 34.2 | - | 29.3 | 18.1 | 8.0 | - | 19.4 | 10.1 | 6.2 | - | 31.6 | 30.6 | 65.9 | - | 26.3 | 312.8 | 103.2 | - | 594.6 | 445.2 | 179.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
574.4 | - | 309.5 | 304.6 | 376.8 | - | 286.0 | 286.2 | 371.0 | - | 385.6 | 312.5 | 393.6 | 73.3 | 1132.1 | 1127.2 | 993.2 | 101.1 | 237.3 | 1565.8 | 581.8 | 45.5 | 3405.1 | 2547.3 | 492.2 | 10.7 | 31.7 | 59.8 | 58.4 | 36.7 | 44.9 | 42.9 | 51.6 | 75.8 | 142.3 | 68.2 | 101.6 | 27.5 | 57.2 | 45.4 | 69.6 | 66.4 | 51.8 | 57.4 | 95.6 | 65.8 | 268.6 | 184.7 | 110.2 | 85.6 | 9.0 | 8.9 | - |
Cash Conversion Cycle |
534.0 | - | 285.0 | 287.5 | 342.6 | - | 256.7 | 268.0 | 362.9 | - | 366.3 | 302.4 | 387.4 | 73.3 | 1100.5 | 1096.5 | 927.3 | 101.1 | 211.0 | 1253.0 | 478.7 | 45.5 | 2810.5 | 2102.1 | 312.4 | 10.7 | 31.7 | 59.8 | 58.4 | 36.7 | 44.9 | 42.9 | 51.6 | 75.8 | 142.3 | 68.2 | 101.6 | 27.5 | 57.2 | 45.4 | 69.6 | 66.4 | 51.8 | 57.4 | 95.6 | 65.8 | 268.6 | 184.7 | 110.2 | 85.6 | 9.0 | 8.9 | - |
All numbers in USD currency